Clinical Trial: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Phase II Trial of Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin (GIFOX-B)in Untreated NK/T Cell Lymphoma
Brief Summary:
- Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage III - IV.
- Assess the toxicity and maximum tolerated dose of bortezomib administered in combination with GIFOX chemotherapy.